Expert Covers Burgeoning Role of CAR T-Cell Therapy in Myeloma – OncLive
OncLive |
Expert Covers Burgeoning Role of CAR T-Cell Therapy in Myeloma
OncLive Chimeric antigen receptor (CAR) T-cell therapy has demonstrated potential for patients with relapsed/refractory multiple myeloma, and improvements in efficacy and safety may facilitate its transition into earlier-stage settings, says Maung Myo Htut, MD. What’s the Total Cost of One CAR T-Cell Treatment? – MedscapeMedscape CAR-T 2.0? A split, universal and programmable system …FierceBiotech Analysis determines true cost for CAR T-cell therapy – HealioHealio Endpoints News –Medical Xpress all 8 news articles » |